Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
Topic
Cancer Medicine
22 articles on Cancer Medicine, written for patients and carers arranging specialty treatment.
-
-
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026. n This marks an important milestone
-
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026. n Brain tumors, especially high-grade gliomas,
-
What are the 4 stages of lung cancer?
Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 7, 2026. n Lung cancer staging is a
-
Sunvozertinib vs Chemo: A PFS Breakthrough in EGFR+ NSCLC
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 25, 2026. n The treatment landscape for EGFR-mutated
-
Atirmociclib and Fulvestrant Together Delay Cancer Progression in HR+/HER2– Cases
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 23, 2026. Advancements in breast cancer treatment continue
-
ESGO 2026 Insights: The Future of Ovarian Cancer Care
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 14, 2026. n The 27th European Congress on
-
Trifluridine/Tipiracil-Associated Neutropenia in Metastatic Colorectal Cancer: What It Means for Treatment Outcomes
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 10, 2026. n Metastatic colorectal cancer (mCRC) remains
-
New Hope for Advanced Prostate Cancer: Enzalutamide and Radium-223 Combination Shows Survival Benefit
Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 5, 2026. n Advances in prostate cancer treatment
-
Zongertinib Receives FDA Accelerated Approval for HER2+ NSCLC Treatment
Medical Review: This article was reviewed by Dr. Sophie Reynolds on February 28, 2026. n The U.S. Food and Drug
Still have a question?
We reply to every enquiry within one working day.